Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Breast cancer
HER2 low
HER2 zero
Neoadjuvant chemotherapy
Pathologic complete response
Journal
Breast cancer (Tokyo, Japan)
ISSN: 1880-4233
Titre abrégé: Breast Cancer
Pays: Japan
ID NLM: 100888201
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
10
06
2023
accepted:
28
07
2023
medline:
23
10
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
ppublish
Résumé
Breast cancers without HER2 amplification but still expressing this membrane protein constitute a new entity called HER2-low tumors. It is important to characterize them in terms of sensitivity to treatment and prognosis. To investigate chemosensitivity and long-term prognosis of HER2-low early breast cancer (eBC), compared to HER2-0 tumors, we retrospectively retrieved clinicopathological characteristics, response to treatment, and survival data from 511 patients treated for eBC with neoadjuvant chemotherapy (NAC) in a French cancer center between 2007 and 2018. Factors associated with the achievement of pathologic complete response (pCR) and survival were studied among hormone receptor positive (HR+) and negative (HR-) eBC. A total of 280 HR+ (61% HER2-low), and 231 HR- (28% HER2-low) eBC were included. We found classical clinicopathological factors usually associated with chemosensitivity and prognosis, in both HR+ and HR- eBC. By uni- and multivariable analysis, HER2 status (low vs 0) was not independently associated with pCR, either in HR+ or HR- eBC. Relapse free (RFS) and overall survival (OS) were not significantly different between HER2-low and HER2-0 among HR+ tumors. In contrast, among HR- negative tumors, RFS and OS were slightly better in HER2-0 eBC by univariable but not by multivariable analysis. In eBC patients treated with NAC, taking into account HR expression subtype and other current clinicopathological features, HER2-low tumors did not appear to have different chemosensitivity or prognosis, compared to their HER2-0 counterparts.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancers without HER2 amplification but still expressing this membrane protein constitute a new entity called HER2-low tumors. It is important to characterize them in terms of sensitivity to treatment and prognosis.
PATIENTS AND METHODS
METHODS
To investigate chemosensitivity and long-term prognosis of HER2-low early breast cancer (eBC), compared to HER2-0 tumors, we retrospectively retrieved clinicopathological characteristics, response to treatment, and survival data from 511 patients treated for eBC with neoadjuvant chemotherapy (NAC) in a French cancer center between 2007 and 2018. Factors associated with the achievement of pathologic complete response (pCR) and survival were studied among hormone receptor positive (HR+) and negative (HR-) eBC.
RESULTS
RESULTS
A total of 280 HR+ (61% HER2-low), and 231 HR- (28% HER2-low) eBC were included. We found classical clinicopathological factors usually associated with chemosensitivity and prognosis, in both HR+ and HR- eBC. By uni- and multivariable analysis, HER2 status (low vs 0) was not independently associated with pCR, either in HR+ or HR- eBC. Relapse free (RFS) and overall survival (OS) were not significantly different between HER2-low and HER2-0 among HR+ tumors. In contrast, among HR- negative tumors, RFS and OS were slightly better in HER2-0 eBC by univariable but not by multivariable analysis.
CONCLUSIONS
CONCLUSIONS
In eBC patients treated with NAC, taking into account HR expression subtype and other current clinicopathological features, HER2-low tumors did not appear to have different chemosensitivity or prognosis, compared to their HER2-0 counterparts.
Identifiants
pubmed: 37561255
doi: 10.1007/s12282-023-01490-1
pii: 10.1007/s12282-023-01490-1
pmc: PMC10587331
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
997-1007Informations de copyright
© 2023. The Author(s).
Références
Eur J Cancer. 2022 Nov;176:181-188
pubmed: 36257173
Cancer Discov. 2022 Sep 2;12(9):2026-2030
pubmed: 35856622
J Clin Oncol. 2008 Jan 10;26(2):246-52
pubmed: 18056680
J Clin Oncol. 2020 Jun 10;38(17):1951-1962
pubmed: 32330069
Cancers (Basel). 2021 Jun 05;13(11):
pubmed: 34198891
JCO Oncol Pract. 2021 Oct;17(10):594-604
pubmed: 34077236
NPJ Breast Cancer. 2021 Jan 4;7(1):1
pubmed: 33397968
JAMA Oncol. 2022 Aug 1;8(8):1177-1183
pubmed: 35737367
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
Eur J Cancer. 2022 Nov;176:30-40
pubmed: 36183652
Arch Pathol Lab Med. 2007;131(1):18-43
pubmed: 19548375
Breast Cancer Res. 2021 Dec 14;23(1):112
pubmed: 34906198
Mod Pathol. 2023 Apr;36(4):100087
pubmed: 36788086
Breast. 2013 Jun;22(3):301-8
pubmed: 22863283
JAMA Oncol. 2023 Apr 1;9(4):500-510
pubmed: 36821125
Breast Cancer Res Treat. 2021 Nov;190(1):155-163
pubmed: 34409551
Lancet Oncol. 2021 Aug;22(8):1151-1161
pubmed: 34252375
Breast. 2023 Feb;67:1-7
pubmed: 36535072
JCO Oncol Pract. 2021 Oct;17(10):605-606
pubmed: 34077256
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Cancers (Basel). 2021 Dec 01;13(23):
pubmed: 34885167
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Lancet. 2017 Jun 17;389(10087):2415-2429
pubmed: 27939064
Eur J Cancer. 2016 Jan;53:65-74
pubmed: 26693900
Clin Cancer Res. 2020 Jun 15;26(12):2838-2848
pubmed: 32046998
Crit Rev Oncol Hematol. 2021 Apr;160:103280
pubmed: 33667658
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Breast Cancer. 2022 Mar;29(2):234-241
pubmed: 34622383
JCO Oncol Pract. 2021 Jun;17(6):320-330
pubmed: 34111378